Collagen Solutions plc

Equities

COS

GB00B94T6Y14

Delayed London S.E. Other stock markets 11:35:02 2020-11-16 am EST			5-day change	1st Jan Change
6.625 ^GBX	-.--%		-.--%	+94.85%

2020	Australia shares set to snap three-day losing streak; NZ up	RE
2020	Rosen's Diversified Inc. completed the acquisition of remaining 81.3% stake in Collagen Solutions plc from a group of shareholders.	CI

Collagen : NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON

November 17, 2020 at 04:49 am EST

At the request of the Company the following securities have been cancelled from trading on AIM with effect from the time and date of this notice.

COLLAGEN SOLUTIONS PLC

213800IFY1CVGRGETL95

ORDINARY SHARES OF 1P EACH FULLY PAID

(B94T6Y1)(GB00B94T6Y14)

COLN SOLU/PAR VTG FPD 0.01

If you have any queries or require further information, please contact the company's nominated adviser on 0207 397 8900.

Attachments

Original document
Permalink

Disclaimer

Collagen Solutions plc published this content on 17 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2020 09:48:03 UTC

Latest news about Collagen Solutions plc

Australia shares set to snap three-day losing streak; NZ up	20-12-22	RE
Rosen's Diversified Inc. completed the acquisition of remaining 81.3% stake in Collagen Solutions plc from a group of shareholders.	20-10-18	CI
Rosen's Diversified Inc. reached an agreement to acquire remaining 81.3% stake in Collagen Solutions plc from a group of shareholders for £23.6 million.	20-08-26	CI
Collagen Solutions plc Announces Unaudited Consolidated Earnings Results for the Year Ended 31 March 2020	20-07-31	CI
Collagen Solutions plc Provides Sales Guidance for the First Quarter of 2021	20-07-31	CI
Collagen Solutions Plc Supply Agreement with NovaBone Products	20-07-07	CI
Collagen Solutions Plc Completes £0.5 million Investment in the Glasgow Facility	20-06-15	CI
Collagen Solutions Updates on Strategic Review and Formal Sale Process	20-05-18	CI
Collagen Solutions plc Provides Revenue Guidance for the Year Ended March 31, 2020	20-04-23	CI
Collagen Solutions Seeks Strategic Review	20-04-16	CI
Collagen Solutions plc Provides Earnings Guidance for the Ending March 31, 2020	20-03-18	CI
Devro : Sausage-skin maker Devro says China plant operating at normal capacity	20-03-04	RE
Collagen Solutions plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 September 2019	19-12-03	CI
Collagen Solutions plc Announces Directorate Change	19-11-13	CI
Collagen Solutions plc Provides Revenue Guidance for the First Half Ended September 30, 2019	19-10-22	CI
Collagen Solutions plc Announces Directorate Change	19-07-09	CI
Collagen Solutions plc Reports Audited Consolidated Earnings Results for the Year Ended 31 March 2019	19-07-09	CI
Collagen Solutions plc Announces Appointment of Wade Rosen as Non-Executive Director	19-06-06	CI
Collagen Solutions plc Provides Revenue Guidance for the Full Year of 2019	19-04-09	CI
An undisclosed buyer acquired an unknown minority stake in Jellagen Ltd from Collagen Solutions plc for £0.22 million.	19-02-19	CI
PT Rajawali Medika Enters into Licensing Agreement with Collagen Solutions Plc	19-01-31	CI
Collagen Solutions plc Enters into New Agreement with Olaregen Therapeutix Inc. to Manufacture and Produce Excellagen	19-01-15	CI
Collagen Solutions plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2018	18-12-04	CI
Collagen Solutions plc Announces Amendments to its 2017 Bond Subscription Agreement	18-11-05	CI
Collagen Solutions plc Provides an Update on Trading for the Six Months to 30 September 2018	18-10-23	CI

Chart Collagen Solutions plc

Duration

Period

More charts

Company Profile

Collagen Solutions plc is a holding company. The Company is engaged in the business of supply, development and manufacture of medical grade collagen components and biomaterials. The Company's products and services are utilized in the research, diagnostics, medical devices and regenerative medicine markets. The Company's main products include Collagen and tissue biomaterials. The Company's product range includes raw tissue supply, including pericardium, which is used in heart valves and dural patches, various strengths of soluble and acid soluble collagen, acid swollen gels, freeze-dried powders, collagen sheets and fibrous collagen. The Company also manufactures Excellagen, a collagen gel used in wound care and cell therapy fields. Its services include product development and contract manufacturing. It offers a range of bovine spongiform encephalopathy (BSE)-free bovine biomaterials to meet customer specifications, including bone, cartilage and tendon, and veins and blood vessels.

Sector

More about the company